RRM2 and glioblastoma: The analysis indicated that glioblastoma patients exhibiting genomic alterations in PCNA clamp-associated factor (PCLAF), RRM2, nucleolar and spindle-associated protein 1 (NUSAP1), and KIF23 displayed reduced overall survival rates, as shown in Fig. (3).